Nocturnal activity with nighttime pergolide in Parkinson disease: A controlled study using actigraphy

Cynthia L. Comella*, Mary Morrissey, Kimberly Janko

*Corresponding author for this work

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

Pergolide is a dopamine agonist that improves Parkinson disease but is associated with dose-dependent sleepiness. This study evaluates the effect of a nighttime dose of 1 mg of pergolide on actigraphic measures of sleep using a randomized, double-blind, placebo-controlled study design. The pergolide group (n = 10) worsened in actigraphic measures of sleep efficiency and sleep fragmentation vs the placebo group (n = 12). Side effects were more frequent in the pergolide group.

Original languageEnglish (US)
Pages (from-to)1450-1451
Number of pages2
JournalNeurology
Volume64
Issue number8
DOIs
StatePublished - Apr 26 2005

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Nocturnal activity with nighttime pergolide in Parkinson disease: A controlled study using actigraphy'. Together they form a unique fingerprint.

  • Cite this